Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Association of ESR1 Mutations and Visceral Metastasis in Patients with Estrogen Receptor-Positive Advanced Breast Cancer from Brazil.

Reinert T, Coelho GP, Mandelli J, Zimermann E, Zaffaroni F, Bines J, Barrios CH, Graudenz MS.

J Oncol. 2019 Aug 14;2019:1947215. doi: 10.1155/2019/1947215. eCollection 2019.

2.

Iron concentrations in neurons and glial cells with estimates on ferritin concentrations.

Reinert A, Morawski M, Seeger J, Arendt T, Reinert T.

BMC Neurosci. 2019 May 29;20(1):25. doi: 10.1186/s12868-019-0507-7.

3.

Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, Heilskov Rasmussen M, Vang S, Shchegrova S, Frydendahl Boll Johansen A, Srinivasan R, Assaf Z, Balcioglu M, Olson A, Dashner S, Hafez D, Navarro S, Goel S, Rabinowitz M, Billings P, Sigurjonsson S, Dyrskjøt L, Swenerton R, Aleshin A, Laurberg S, Husted Madsen A, Kannerup AS, Stribolt K, Palmelund Krag S, Iversen LH, Gotschalck Sunesen K, Lin CJ, Zimmermann BG, Lindbjerg Andersen C.

JAMA Oncol. 2019 May 9. doi: 10.1001/jamaoncol.2019.0528. [Epub ahead of print] Erratum in: JAMA Oncol. 2019 Jun 13;:.

4.

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.

Christensen E, Birkenkamp-Demtröder K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV, Taber A, Balcioglu M, Vang S, Assaf Z, Sharma S, Tin AS, Srinivasan R, Hafez D, Reinert T, Navarro S, Olson A, Ram R, Dashner S, Rabinowitz M, Billings P, Sigurjonsson S, Andersen CL, Swenerton R, Aleshin A, Zimmermann B, Agerbæk M, Lin CJ, Jensen JB, Dyrskjøt L.

J Clin Oncol. 2019 Jun 20;37(18):1547-1557. doi: 10.1200/JCO.18.02052. Epub 2019 May 6.

PMID:
31059311
5.

Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab.

Barrios CH, Reinert T, Werutsky G.

Ecancermedicalscience. 2019 Jan 22;13:898. doi: 10.3332/ecancer.2019.898. eCollection 2019. Review.

6.

Global Breast Cancer Research: Moving Forward.

Barrios CH, Reinert T, Werutsky G.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:441-450. doi: 10.1200/EDBK_209183. Review.

PMID:
30231347
7.

Note: Performance of a novel electrostatic quadrupole doublet for nuclear microprobe application.

Manuel JE, Szilasi SZ, Byers TA, Phillips DZ, Dymnikov AD, Reinert T, Rout B, Glass GA.

Rev Sci Instrum. 2018 Aug;89(8):086103. doi: 10.1063/1.5017824.

PMID:
30184660
8.

Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.

Reinert T, de Paula B, Shafaee MN, Souza PH, Ellis MJ, Bines J.

Chin Clin Oncol. 2018 Jun;7(3):25. doi: 10.21037/cco.2018.06.06. Review.

9.

Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.

Debiasi M, Polanczyk CA, Ziegelmann P, Barrios C, Cao H, Dignam JJ, Goss P, Bychkovsky B, Finkelstein DM, Guindalini RS, Filho P, Albuquerque C, Reinert T, de Azambuja E, Olopade O.

Front Oncol. 2018 May 22;8:156. doi: 10.3389/fonc.2018.00156. eCollection 2018. Review.

10.

The Challenge of Evaluating Adnexal Masses in Patients With Breast Cancer.

Reinert T, Nogueira-Rodrigues A, Kestelman FP, Ashton-Prolla P, Graudenz MS, Bines J.

Clin Breast Cancer. 2018 Aug;18(4):e587-e594. doi: 10.1016/j.clbc.2018.03.006. Epub 2018 Mar 12. Review.

PMID:
29680194
11.

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.

Reinert T, Gonçalves R, Bines J.

Curr Treat Options Oncol. 2018 Apr 17;19(5):24. doi: 10.1007/s11864-018-0542-0. Review.

PMID:
29666928
12.

Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Reinert T, Gonçalves R, Ellis MJ.

Curr Treat Options Oncol. 2018 Apr 16;19(5):23. doi: 10.1007/s11864-018-0538-9. Review.

PMID:
29663173
13.

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review.

Reinert T, Barrios CH.

Ther Adv Med Oncol. 2017 Nov;9(11):693-709. doi: 10.1177/1758834017728928. Epub 2017 Sep 8. Review.

14.

Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.

Cruz M, Reinert T, Cristofanilli M.

Clin Pharmacol Ther. 2018 Jun;103(6):1009-1019. doi: 10.1002/cpt.965. Epub 2018 Jan 30. Review.

PMID:
29226311
15.

Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone receptor-positive advanced breast cancer.

Reinert T, Debiasi M, Bines J, Barrios CH.

Breast Cancer Res Treat. 2018 Apr;168(2):457-465. doi: 10.1007/s10549-017-4593-x. Epub 2017 Nov 30. Review.

PMID:
29190006
16.

Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.

17.

Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System.

Debiasi M, Reinert T, Kaliks R, Amorim G, Caleffi M, Sampaio C, Fernandes GDS, Barrios CH.

J Glob Oncol. 2016 Jul 20;3(3):201-207. doi: 10.1200/JGO.2016.005678. eCollection 2017 Jun.

18.

Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.

Schøler LV, Reinert T, Ørntoft MW, Kassentoft CG, Árnadóttir SS, Vang S, Nordentoft I, Knudsen M, Lamy P, Andreasen D, Mortensen FV, Knudsen AR, Stribolt K, Sivesgaard K, Mouritzen P, Nielsen HJ, Laurberg S, Ørntoft TF, Andersen CL.

Clin Cancer Res. 2017 Sep 15;23(18):5437-5445. doi: 10.1158/1078-0432.CCR-17-0510. Epub 2017 Jun 9.

19.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
20.

Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.

Goncalves R, Reinert T, Ellis MJ.

J Clin Oncol. 2017 Aug 10;35(23):2718-2719. doi: 10.1200/JCO.2017.73.0424. Epub 2017 Jun 5. No abstract available.

PMID:
28581884
21.

Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.

Reinert T, Saad ED, Barrios CH, Bines J.

Front Oncol. 2017 Mar 15;7:26. doi: 10.3389/fonc.2017.00026. eCollection 2017. Review.

22.

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review.

Reinert T, Ramalho S, Gonçalves R, Barrios CH, Graudenz MS, Bines J.

Rev Bras Ginecol Obstet. 2016 Dec;38(12):615-622. doi: 10.1055/s-0036-1597579. Epub 2016 Dec 21. Review.

23.

Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.

Coelho RC, Reinert T, Campos F, Peixoto FA, de Andrade CA, Castro T, Herchenhorn D.

Int Braz J Urol. 2016 Jul-Aug;42(4):694-703. doi: 10.1590/S1677-5538.IBJU.2015.0226.

24.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

25.

Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer.

Reinert T, Barrios CH.

J Clin Oncol. 2016 Jun 1;34(16):1959-60. doi: 10.1200/JCO.2015.66.0803. Epub 2016 Mar 21. No abstract available.

PMID:
27001564
26.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, Borre M, Agerbæk M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Eur Urol. 2016 Jul;70(1):75-82. doi: 10.1016/j.eururo.2016.01.007. Epub 2016 Jan 20.

PMID:
26803478
27.

Ion exchanger in the brain: Quantitative analysis of perineuronally fixed anionic binding sites suggests diffusion barriers with ion sorting properties.

Morawski M, Reinert T, Meyer-Klaucke W, Wagner FE, Tröger W, Reinert A, Jäger C, Brückner G, Arendt T.

Sci Rep. 2015 Dec 1;5:16471. doi: 10.1038/srep16471.

28.

Optimal management of hormone receptor positive metastatic breast cancer in 2016.

Reinert T, Barrios CH.

Ther Adv Med Oncol. 2015 Nov;7(6):304-20. doi: 10.1177/1758834015608993. Review.

29.

Mechanisms of aromatase inhibitor resistance.

Ma CX, Reinert T, Chmielewska I, Ellis MJ.

Nat Rev Cancer. 2015 May;15(5):261-75. doi: 10.1038/nrc3920. Review.

PMID:
25907219
30.

Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.

Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Ørntoft TF, Andersen CL.

Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.

PMID:
25654990
31.

Crystal structure of catena-poly[[(3-tert-butyl-pyridine-κN)(4-tert-butyl-pyridine-κN)cadmium]-di-μ-thio-cyanato-κ(2) N:S;κ(2) S:N].

Werner J, Reinert T, Jess I, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2014 Nov 19;70(Pt 12):m403-4. doi: 10.1107/S1600536814024647. eCollection 2014 Dec 1.

32.

Mutational context and diverse clonal development in early and late bladder cancer.

Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Ørntoft TF.

Cell Rep. 2014 Jun 12;7(5):1649-1663. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.

33.

Estimating upper bounds for occupancy and number of manatees in areas potentially affected by oil from the Deepwater Horizon oil spill.

Martin J, Edwards HH, Bled F, Fonnesbeck CJ, Dupuis JA, Gardner B, Koslovsky SM, Aven AM, Ward-Geiger LI, Carmichael RH, Fagan DE, Ross MA, Reinert TR.

PLoS One. 2014 Mar 26;9(3):e91683. doi: 10.1371/journal.pone.0091683. eCollection 2014.

34.

Depolarizing chloride gradient in developing cochlear nucleus neurons: underlying mechanism and implication for calcium signaling.

Witte M, Reinert T, Dietz B, Nerlich J, Rübsamen R, Milenkovic I.

Neuroscience. 2014 Mar 7;261:207-22. doi: 10.1016/j.neuroscience.2013.12.050. Epub 2014 Jan 3.

PMID:
24388924
35.

Poly[(aceto-nitrile-κN)-μ3-thio-cyanato-κ(3) N:S:S-μ2-thio-cyanato-κ(2) N:S-cadmium].

Reinert T, Jess I, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2013 Jun 15;69(Pt 7):m398. doi: 10.1107/S1600536813015870. eCollection 2013.

36.
37.

Bis-(3-tert-butyl-pyridine-κN)bis-(4-tert-butyl-pyridine-κN)bis(thio-cyanato-κN)cadmium.

Reinert T, Jess I, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2012 Nov 1;68(Pt 11):m1372. doi: 10.1107/S1600536812040081. Epub 2012 Oct 20.

38.

Trans-bis-(3-tert-butyl-pyridine-κN)bis-(4-tert-butyl-pyridine-κN)bis-(thio-cyanato-κN)manganese(II).

Reinert T, Jess I, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2012 Nov 1;68(Pt 11):m1333. doi: 10.1107/S1600536812041128. Epub 2012 Oct 6.

39.

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC.

J Urol. 2013 May;189(5):1945-51. doi: 10.1016/j.juro.2012.11.115. Epub 2012 Nov 28.

PMID:
23201384
40.

Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.

Fristrup N, Birkenkamp-Demtröder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J, Alvarez-Múgica M, Pan CC, Ulhøi BP, Borre M, Ørntoft TF, Dyrskjøt L.

Am J Pathol. 2013 Feb;182(2):339-49. doi: 10.1016/j.ajpath.2012.10.017. Epub 2012 Nov 28.

PMID:
23201130
41.

Diagnosis of bladder cancer recurrence based on urinary levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 hypermethylation.

Reinert T, Borre M, Christiansen A, Hermann GG, Ørntoft TF, Dyrskjøt L.

PLoS One. 2012;7(10):e46297. doi: 10.1371/journal.pone.0046297. Epub 2012 Oct 3.

42.

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.

Dyrskjøt L, Reinert T, Novoradovsky A, Zuiverloon TC, Beukers W, Zwarthoff E, Malats N, Real FX, Segersten U, Malmström PU, Knowles M, Hurst C, Sorge J, Borre M, Orntoft TF.

Br J Cancer. 2012 Oct 9;107(8):1392-8. doi: 10.1038/bjc.2012.412. Epub 2012 Sep 13.

43.

A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.

Schepeler T, Lamy P, Hvidberg V, Laurberg JR, Fristrup N, Reinert T, Bartkova J, Tropia L, Bartek J, Halazonetis TD, Pan CC, Borre M, Dyrskjøt L, Orntoft TF.

Oncogene. 2013 Aug 1;32(31):3577-86. doi: 10.1038/onc.2012.381. Epub 2012 Aug 27.

PMID:
22926521
45.

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.

Dyrskjøt L, Zieger K, Kissow Lildal T, Reinert T, Gruselle O, Coche T, Borre M, Ørntoft TF.

Br J Cancer. 2012 Jun 26;107(1):116-22. doi: 10.1038/bjc.2012.215. Epub 2012 May 17.

46.

Poly[bis-(μ(2)-pyrimidine-κN:N')bis-(seleno-cyanato-κN)zinc].

Boeckmann J, Reinert T, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2011 Jul 1;67(Pt 7):m948. doi: 10.1107/S1600536811023129. Epub 2011 Jun 18.

47.

Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.

Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjøt L, Orntoft TF.

Clin Cancer Res. 2011 Sep 1;17(17):5582-92. doi: 10.1158/1078-0432.CCR-10-2659. Epub 2011 Jul 25.

48.

Bis(pyridazine-κN)bis-(seleno-cyanato-κN)zinc.

Reinert T, Boeckmann J, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2011 May 1;67(Pt 5):m567. doi: 10.1107/S1600536811012621. Epub 2011 Apr 13.

49.

On the quantification of intracellular proteins in multifluorescence-labeled rat brain slices using slide-based cytometry.

Reinert A, Mittag A, Reinert T, Tárnok A, Arendt T, Morawski M.

Cytometry A. 2011 Jun;79(6):485-91. doi: 10.1002/cyto.a.21047. Epub 2011 Mar 18.

50.

catena-Poly[[μ(3)-hydroxido-tetra-μ(2)-pyrid-azine-1:2κN:N';1:3κN:N';2:3κN:N'-tetrakis(selenocyanato)-1κN,2κN,3κN-trizinc(II)]-μ-cyanido-1:2'κC:N].

Reinert T, Boeckmann J, Jess I, Näther C.

Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 24;66(Pt 8):m1018-9. doi: 10.1107/S1600536810029107.

Supplemental Content

Loading ...
Support Center